REFERENCES
- Ibrahim, H N.; Hostetter, T H. Diabetic nephropathy.J. Am. Soc. Nephrol. 1997, 8, 487–493. [PUBMED], [INFOTRIEVE], [CSA]
- Ziyadeh, F N. The extracellular matrix in diabetic nephropathy.Am. J. Kidney Dis. 1993, 22, 736–744. [PUBMED], [INFOTRIEVE], [CSA]
- Ha, H.; Kim, K H. Role of oxidative stress in the development of diabetic nephropathy.Kidney Int. 1995, 48 (Suppl. 51), S18–S21. [CSA]
- Larkins, R G.; Dunlop, M E. The link between hyperglycemia and diabetic nephropathy.Diabetologia 1992, 35, 499–504. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ruiz, C.; Alegria, A.; Barbera, R.; Farre, R.; Lagarda, M J. Lipid peroxidation and antioxidant enzyme activities in patients with type-I diabetes mellitus.Scand. J. Clin. Lab. Invest. 1994, 59, 99–105.
- Ruiz-Munoz, L M.; Vidal-Vanacloch, F.; Lampreabe, I. Enalapril inhibits hydrogen-peroxide production by murine mesangial cells exposed to high glucose concentration.Nephrol. Dial. Transplant. 1997, 12, 456–464. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ha, H.; Lee, S H.; Kim, K H. Effects of rebamipide in a model of experimental diabetes and on the synthesis of transforming growth factor-beta and fibronectin, lipid peroxidation induced y high glucose in cultured mesangial cells.J. Pharm. Exp. Ther. 1997, 28, 1462–1497.
- Hunt, J V.; Bottoms, M A.; Mitchinson, M J. Oxidative alterations in the experimental glycation model of diabetes mellitus are due to protein-glucose adduct oxidation: some fundamental differences in proposed mechanism of glucose oxidation and oxidant production.Biochem. J. 1993, 291, 259–262.
- Baynes, J W. Role of oxidative stress in development of complication in diabetes.Diabetes 1991, 40, 405–412. [PUBMED], [INFOTRIEVE]
- Cooper, M E. Interaction of metabolic and homodynamic factors in mediating experimental diabetic nephropathy.Diabetologia 2001, 44, 1957–1972. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kasiske, B L.; O'Donnell, M P.; Keane, W F. Renal effects of angiotensin II: modulation by calcium and cyclooxygenase products.Am. J. Physiol. 1986, 251 (20), F1043–F1048., [PUBMED], [INFOTRIEVE]
- Mene, P.; Simonson, M S.; Dunn, M J. Physiology of the mesangial cell.Physiol. Rev. 1989, 69, 1347–1424. [PUBMED], [INFOTRIEVE]
- Parving, H H.; Lehnert, H.; Brochner-Mortensen, J.; Gomis, R.; Andersen, S.; Arner, P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.N. Engl. J. Med. 2001, 345, 870–878. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wolf, G.; Ziyadesh, F N. The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms.Am. J. Kidney Dis. 1997, 29, 153–163. [PUBMED], [INFOTRIEVE], [CSA]
- Yavuz, D.; Kucukkaya, B.; Haklar, G.; Ersoz, O.; Akoglu, E.; Akalin, S. Effects of captopril and losartan on lipid peroxidation, protein oxidation and nitric oxide release in diabetic rat kidney.Prostaglandins Leukot. Essent Fatty Acids 2003, 69, 223–227. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Elena, M V.; de, Cavanagh; Inserra, F.; Toblli, J.; Stella, I.; Fraga, C G.; Ferder, L. Enalapril attenuates oxidative stress in diabetic rats.Hypertension 2001, 38, 1130–1136.
- Anjaneyulu, M.; Chopra, K. Effect of irbesartan on the antioxidant defense system and nitric oxide release in diabetic rat kidney.Am. J. Nephrol. 2004a, 24 (5), 488–496. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gaber, L.; Walton, C.; Brown, S.; Bakris, G. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs.Kidney Int. 1994, 46, 161–169. [PUBMED], [INFOTRIEVE]
- Brown, S A.; Walton, C L.; Crawford, P.; Bakris, G L. Long-term effects of antihypertensive regimens on renal hemodynamic and proteinuria.Kidney Int. 1993, 43, 1210–1218. [PUBMED], [INFOTRIEVE]
- Luno, J.; Garcia, D E.; Vinuesa, S.; Gomez-Campdera, F.; Lorenzo, I.; Valderrabano, F. Effects of antihypertensive therapy on progression of diabetic nephropathy.Kidney Int. 1998, 68 (Suppl.), S112–S119. [CROSSREF], [CSA]
- Baba, T.; Murabayshi, S.; Takabe, K. Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonists in hypertension type 2 diabetic patients with microalbuminuria: a randomized controlled trial.Diabetologia 1989, 32, 40–44. [PUBMED], [INFOTRIEVE], [CSA]
- Bakris, G L.; Copley, J B.; Vicknair, N.; Sadler, R.; Leurgans, S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy.Kidney Int. 1996, 50, 1641–1650. [PUBMED], [INFOTRIEVE]
- Anjaneyulu, M.; Chopra, K. Nordihydroguairetic acid, a lignin, prevents oxidative stress and the development of diabetic nephropathy in rats.Pharmacology 2004b, 72, 42–50. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kedziora-kornatowska, K.; Szram, S.; Kornatowski, T.; Szadujkis-Szadurski, L.; Kedziora, J.; Bartosz, G. The effect of verapamil on the antioxidant defense system in diabetic kidney.Clin. Chim. Acta 2002, 322, 105–112. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Schmidt, F H. Methodon der harn-und blutzuckerbestrimmung II: Handbuch Des.Diabetes Mellitus 1971, 2, 938. [CSA]
- Anjaneyulu, M.; Ramarao, P. Studies on gastrointestinal tract functional changes in diabetic animals.Methods Find Exp. Clin. Pharmacol. 2002, 2, 71–75.
- Wills, E D. Mechanism of lipid peroxide formation in animal tissues.Biochem. J. 1996, 99, 667–676.
- Owens, L.; Belcher, R V. A colorimetric micro-method for the determination of glutathione.Biochem. J. 1965, 94, 75–79.
- Kono, Y. Generation of superoxide radical during autooxidation of hydroxylamine and an assay for superoxide dismutase.Arch. Biochem. Biophy. 1978, 186, 189–195. [CROSSREF]
- Luck, H. Catalase. Methods of Enzymatic Analysis; Bergmeyer, H U., Ed.; Academic Press: New York, 1971; 885–893.
- Lowry, O H.; Rosen-Brough, N J.; Farr, A L.; Randall, R J. Protein measurement with the Folin-Phenol reagent.J. Biol. Chem. 1951, 193, 265–275. [PUBMED], [INFOTRIEVE]
- Raghvendra, V.; Agrewala, J N.; Kulkarni, S K. Melatonin reversal of lipopolysaccharide-induced thermal and behavioral hyperalgesia in mice.Eur. J. Pharmacol. 2000, 395, 15–21. [CROSSREF]
- Adler, A I.; Stratton, I M.; Neil, H A.; Yudkin, J S.; Matthews, D R.; Cull, C A.; Wright, A D.; Turner, R C.; Holman, R R. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.Br. Med. J. 2000, 321, 412–419.
- Salahudeen, A K.; Kanji, V.; Reckelhoff, J F.; Schmidt, A M. Pathogenesis of diabetic nephropathy: a radical approach.Nephrol. Dial. Transplant. 1997, 12, 664–668. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Anjaneyulu, M.; Chopra, K. Quercetin, an antioxidant bioflavonoid, attenuates diabetic nephropathy in rats.Clin. Exp. Pharmacol. Physiol. 2004c, 31, 244–248. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Trachtman, H.; Futterweit, S.; Bienkowski, R S. Taurine prevents glucose-induced lipidperoxidation and increased collagen production in cultured rat mesangial cells.Biochem. Biophys. Res. Commun. 1993, 199, 759–765., [CROSSREF]
- Padi, S S.; Chopra, K. Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol.Nephron 2002, 92 (3), 685–692. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sugimoto, K.; Tsuruoka, S.; Fujimura, A. Effect of enalapril on diabetic nephropathy in OLETF rats: the role of an anti-oxidative action in its protective properties.Clin. Exp. Pharmacol. Physiol. 2001, 28, 829–830. [CROSSREF]
- Murali, B.; Goyal, R K. Effect of chronic treatment with losartan on streptozotocin induced diabetic nephropathy.Clin. Exp. Hypertens. 2001, 23, 513–520. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kakkar, R.; Mantha, S V.; Radhi, J.; Prasad, K.; Kalra, J. Antioxidant defense system in diabetic kidney: a time course study.Life Sci. 1997, 60, 667–679. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Sukalski, K A.; Pinto, K A.; Berntson, J L. Decreased susceptibility of liver mitochondria from diabetic rats to oxidative damage and associated increase in alpha-tocopherol.Free Radic. Biol. Med. 1993, 14, 57–65. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Arai, K.; Iizuka, S.; Tada, Y.; Oikawa, K.; Taniguchi, N. Increase in the glucosylated form of erythrocyte Cu–Zn-superoxide dismutase in diabetes and close association of the nonenzymatic glycosylation with the enzyme activity.Biochim. Biophys. Acta 1987, 19, 292–296.
- Mene, P. Calcium channel blockers: what they can and what they can not do.Nephrol. Dial. Transplant. 1997, 12, 25–28. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rodicio, J L.; Campo, C.; Ruilope, L M. Renal effects of calcium antagonists.Nephrol. Dial. Transplant. 1995, 10 (Suppl. 9), 17–22. [PUBMED], [INFOTRIEVE]
- Tikkanen, I.; Johnston, C L. Comparison of renin-angiotensin to calcium channel blockade in renal disease.Kidney Int. 1997, 52 (Suppl. 63), S19–S22.
- Paller, M S.; Hoidal, J R.; Ferris, T E. Oxygen free radicals in ischemia acute reanl failure in the rats.J. Clin. Invest. 1984, 72, 1156–1164.
- Craven, P A.; De Rubertis, F R.; Melhem, M. Nitric oxide in diabetic nephropathy.Kidney Int. 1997, 52 (Suppl. 60), S46–S53.
- Pieper, G M. Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine supplementation.Hypertension 1998, 31, 1047–1060. [PUBMED], [INFOTRIEVE], [CSA]
- Onozato, M L.; Tojo, A.; Goto, A.; Fujita, T.; Wilcox, C S. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effect of ACEI and ARB.Kidney Int. 2002, 61, 186–194. [PUBMED], [INFOTRIEVE], [CROSSREF]